KAYLEE NORMAN: Open Payments
NPI 1760195978 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$828 in 28 payments from 7 companies in 2025. Trend: 2023 $32 · 2024 $632 · 2025 $828
Food & beverage: $828
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $305 |
| ABBVIE INC. | 17 | $222 |
| Amgen Inc. | 1 | $120 |
| ACADIA Pharmaceuticals Inc | 1 | $109 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Corium, LLC | 2 | $14 |
Products named: INGREZZA, VRAYLAR, NUPLAZID, REXULTI, FANAPT, Azstarys.
Industry payments across ID — which companies pay providers there.
